Product specific guidances for chloroquine phosphate and hydroxychloroquine sulphate

FDA

13 April 2020 - The FDA plays a critical role in protecting the United States from threats including emerging infectious diseases, such as the coronavirus disease 2019 (COVID-19) pandemic. 

 FDA is committed to providing timely guidance to support response efforts to this pandemic.

In anticipation of increased demand for chloroquine phosphate and hydroxychloroquine sulphate, the FDA is taking steps to ensure that adequate supply of these drug products is available by publishing product-specific guidances to support generic drug development for these drugs.

Read FDA Guidance Document

Michael Wonder

Posted by:

Michael Wonder